Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells.

Hypoxia-inducible factor (HIF) and cyclin D1 are both key mediators of cell growth and proliferation in normal and cancer cells. However, the interrelation between HIF and cyclin D1 remains unclear. In the present study, we observed the inverse correlation between cyclin D1 and HIF-1 in hypoxia condition. Overexpression of the dominant negative mutant of HIF-1alpha (DN-HIF) significantly enhanced cyclin D1 expression upon hypoxia or arsenite exposure, suggesting the negative regulation of cyclin D1 by HIF-1. Furthermore, we found that the impairment of HIF-1 increased cyclin D1 expression in A549 pulmonary cancer cells, which in turn promoted G1-S cell cycle transition and cell proliferation. Cyclin D1 expression was increased in s.c. xenograft of DN-HIF stably transfected A549 cells in nude mice compared with that of control cells. Chromatin immunoprecipitation assay revealed that HIF-1 was able to directly bind to the promoter region of cyclin D1, which indicates that the negative regulation of cyclin D1 by HIF-1 is through a direct mechanism. Inhibition of histone deacetylase (HDAC) by pretreatment of cells with trichostatin A or specific knockdown of HDAC7 by its shRNA antagonized the suppression of cyclin D1 by HIF-1, suggesting that HDAC7 is required for HIF-1-mediated cyclin D1 downregulation. Moreover, we found that 5-fluorouracil-triggered apoptosis of DN-HIF-transfected A549 cells was reduced by sicyclin D1 (cyclin D1-specific interference RNA) introduction, suggesting that clinical observation of HIF-1 overexpression-associated chemoresistance might be, at least partially, due to the negative regulation of cyclin D1.

[1]  Jingxia Li,et al.  PI3K/Akt/JNK/c-Jun signaling pathway is a mediator for arsenite-induced cyclin D1 expression and cell growth in human bronchial epithelial cells. , 2009, Current cancer drug targets.

[2]  Jingxia Li,et al.  Essential roles of PI-3K/Akt/IKKβ/NFκB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells , 2006 .

[3]  C. Haiman,et al.  Cyclin D1: polymorphism, aberrant splicing and cancer risk , 2006, Oncogene.

[4]  P. Schumacker,et al.  Hypoxia-inducible factor-1 (HIF-1). , 2005, Critical care medicine.

[5]  A. Rustgi,et al.  Cyclin D1 Induction through IκB Kinase β/Nuclear Factor-κB Pathway Is Responsible for Arsenite-Induced Increased Cell Cycle G1-S Phase Transition in Human Keratinocytes , 2005 .

[6]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[7]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[8]  K. Blackwell,et al.  Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? , 2004, The oncologist.

[9]  H. Kato,et al.  Histone Deacetylase 7 Associates with Hypoxia-inducible Factor 1α and Increases Transcriptional Activity* , 2004, Journal of Biological Chemistry.

[10]  L. Huang,et al.  HIF‐1α induces cell cycle arrest by functionally counteracting Myc , 2004 .

[11]  Chris Albanese,et al.  Gastrin-mediated activation of cyclin D1 transcription involves β-catenin and CREB pathways in gastric cancer cells , 2004, Oncogene.

[12]  C. Sotiriou,et al.  Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene , 2004, British Journal of Cancer.

[13]  S. Mazumder,et al.  A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. , 2004, Current cancer drug targets.

[14]  G. Powis,et al.  Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.

[15]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[16]  Chi V. Dang,et al.  Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression* , 2001, The Journal of Biological Chemistry.

[17]  T. Clemens,et al.  Hypoxia Induces Vascular Endothelial Growth Factor Gene Transcription in Human Osteoblast-Like Cells through the Hypoxia-Inducible Factor-2α. , 2001, Endocrinology.

[18]  H. Nishimatsu,et al.  Transcriptional Activation of the cyclin D1 Gene Is Mediated by Multiple Cis-Elements, Including SP1 Sites and a cAMP-responsive Element in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[19]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[20]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[21]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[22]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[23]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[25]  Richard J. Lee,et al.  pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. , 1999, The Journal of biological chemistry.

[26]  N. Krucher,et al.  Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities , 1998, Oncogene.

[27]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[28]  D. Fisher,et al.  Regulation of Proliferation-Survival Decisions during Tumor Cell Hypoxia , 1998, Molecular and Cellular Biology.

[29]  G. Semenza,et al.  Transactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α , 1997, The Journal of Biological Chemistry.

[30]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y Fujii-Kuriyama,et al.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Semenza,et al.  Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[33]  John M. Barrie,et al.  The World Wide Web as an Instructional Tool , 1996, Science.

[34]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[35]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[36]  A. Wolffe,et al.  Histone Deacetylase--A Regulator of Transcription , 1996, Science.

[37]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[38]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[39]  Y. Tsujimoto,et al.  Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL , 1995, Nature.

[40]  P. Loidl.  Histone acetylation: facts and questions , 1994, Chromosoma.

[41]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[42]  W. Pledger,et al.  Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. , 1993, Molecular biology of the cell.

[43]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[44]  S. Antonarakis,et al.  Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Goldberg,et al.  Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. , 1988, Science.

[46]  Chenguang Wang,et al.  Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. , 2004, Cancer treatment and research.

[47]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[48]  R. Rickert,et al.  Hypoxia-Inducible Factor 1 (cid:2) Is Essential for Cell Cycle Arrest during Hypoxia , 2002 .

[49]  M. Krasilnikov.  Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. , 2000, Biochemistry. Biokhimiia.

[50]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[51]  Amico,et al.  The cyclin D1 gene is a target of the b-cateninyLEF-1 pathway , 1999 .